Vol. 30 No. 1 (2017), Artykuły
Vol. 30 No. 1 (2017)

Synthesis and characterization of related substances of Azilsartan Kamedoxomil

Artykuły
Published 2017-06-23
N V D Harikiran Maddi
Chemical Research and Development Department, Aurobindo Pharma Ltd, Survey No: 71&72, Indrakaran Village, Sangareddy Mandal, Medak district, Hyderabad – 502329, Andhra Pradesh, India; Department of Engineering Chemistry, A. U. College of Engineering (A), Andhra University, Visakhapatnam – 530 003, Andhra Pradesh, India
Srinivas Garaga
Chemical Research and Development Department, Aurobindo Pharma Ltd, Survey No: 71&72, Indrakaran Village, Sangareddy Mandal, Medak district, Hyderabad – 502329, Andhra Pradesh, India; Department of Engineering Chemistry, A. U. College of Engineering (A), Andhra University, Visakhapatnam – 530 003, Andhra Pradesh, India
Ambati V. Raghava Reddy
Chemical Research and Development Department, Aurobindo Pharma Ltd, Survey No:71&72, Indrakaran Village, Sangareddy Mandal, Medak district, Hyderabad – 502329, Andhra Pradesh, India
Paul Douglas Sanasi
Department of Engineering Chemistry, A. U. College of Engineering (A), Andhra University, Visakhapatnam – 530 003, Andhra Pradesh, India
Raghubabu Korupolu
Department of Engineering Chemistry, A. U. College of Engineering (A), Andhra University, Visakhapatnam – 530 003, Andhra Pradesh, India
PDF

Keywords

Azilsartan Kamedoxomil
related substances
synthesis
characterization

Abstract

Azilsartan Kamedoxomil is an AT1-subtype angiotensin II receptor blocker (ARB). During the laboratory synthesis of Azilsartan Kamedoxomil, four related substances of Azilsartan Kamedoxomil were observed and identified. These were 2-Ethoxy-3-[[4-[2- [4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-5-oxo-1,2,4-oxadiazol-3-yl]phenyl]phenyl] methyl] benzimidazole-4-carboxylic acid (azilsartan N-medoxomil, 9), (5-methyl-2-oxo- 1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-5- oxo-1,2,4-oxadiazol-3-yl]phenyl]phenyl] methyl] benzimidazole-4-carboxylate (azilsartan dimedoxomil, 10), (5-methyl-2-oxo-1,3-dioxo-4-yl)methyl 1-[2’-(4,5-dihydro-5-oxo-4H- 1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-2-methoxy-1H-benzimidazole-7-carboxylate (methoxy analogue of azilsartan medoxomil, 11), Methyl 1-((2’-amidobiphenyl-4-yl) methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (amide methyl ester, 12). The present work describes the origin, synthesis and characterization of these related substances.

PDF

References

1. Aulakh G.K., Sodhi R.K., Singh M.: An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. J. Life Sci., 81, 615, 2007. [Web of Science] [Crossref]

2. Bansal D. et al.: An improved process for the preparation of azilsartan medoxomil. Patent WO/2012/107814, 2012.

3. Dubey S. K. et al.: Indian patent Appl.No.IN2011DE01901 A 20131004.

4. International Conference on Harmonization (ICH) guidelines. Q2B validation of analytical procedure: Methodology. ICH guidelines: Geneva, Switzerland, November, 1996.

5. International Conference on Harmonization (ICH) guidelines. Q3A (R) impurities in New Drug Substances. ICH guidelines: Geneva, Switzerland, February, 2002.

6. Jo N. et al.: A manufacturing method for azilsartan. Patent WO/2012/157980, 2012.

7. Kohara Y. et al.: A new class of angiotensin II receptor antagonists with a novel acidic bioisostere. Bioorg. Med. Chem. Lett., 5, 1903, 1995. [Crossref]

8. Kohara Y. et al.: Synthesis and Angiotensin II Receptor Antagonistic Activities of Benzimidazole Derivatives Bearing Acidic Heterocycles as Novel Tetrazole Bioisosteres. J. Med. Chem., 39, 5228, 1996. [Crossref]

9. Kshirsagar P. B. et al.: The process for the preparation of azilsartanmedoxomil. Patent WO/2013/042066, 2013.

10. Kubo K. et al.: Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids. J. Med. Chem., 36, 2182, 1993. [Crossref]

11. Kuroita T. et al.: Compound which is an angiotensin antagonist. U.S. Patent No.7, 157, 584.

12. Miura S., Karnik S.S., Saku K.: Ability of the new AT1 receotir blocker azilsartan to block angiotensin II-induced AT1 receptor activation after wash-out. J. Renin Angiotensin Aldosterone Syst., 12, 1, 2011. [Crossref]

13. Naka T. K., Inada. Y.: (Takeda Chem. Ind). U.S.Patent No.5, 243, 054. [Web of Science]

14. Radl S. et al.: Synthesis of Azilsartan and its selected potential impurities. J. Heterocyclic Chem., 50, 929, 2013 [Crossref] [Web of Science]

15. Radl S., Stach J.: A method of preparing 2-ethoxy-1-((2’-(5-oxo-4,5- dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)-1H-benzo[d] imidazole-7-carboxylates and conversion thereof to azilsartan. WO/2012/139535. 2012.

16. Raghavareddy A. V. et al.: A novel process for the preparation of Azilsartan medoxomil. Indian patent App. No. 4226/CHE/2012A.

17. Sangeeta S. et al.: Synthesis and Characterization of Impuritiesof a Common and Advanced Intermediate of Candesartan and Azilsartan Antihypertensive Drugs. Int. Res. J. Pure App. Chem., 5, 140, 2015.

18. Sethi M. K. et al.: Related substances of azilsartan medoxomil: synthesis and characterization. Der Pharma Chemica, 7, 20, 2015.

19. Srinivas G. et al.: Commercial synthesis of Azilsartan Kamedoxomil: An angiotensin II receptor blocker. Org. Process Res. Dev., 19, 514, 2015. [Web of Science] [Crossref]

20. Stanislav R. et al.: Improved process for Azilsartan medoxomil: A new angiotensin receptor blocker. Org. Process Res. Dev., 17, 77, 2013. [Web of Science] [Crossref]

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.

Copyright (c) 2017 Authors

Downloads

Download data is not yet available.